Purpose: To describe the efficacy and safety of botulinum toxin A (Botox) in patients with benign essential blepharospasm.
Methods: Retrospective review of operation, injection, and medical records.
Results: Information of 29 patients (nine males) was reviewed, and the average age of benign essential blepharospasm onset was 59.